A Phase 3 interventional study of QL1706 and Placebo in METASTATIC CERVICAL CANCER, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms — 9 open to participants now, 10 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Uterine Cervical Neoplasms.
Among the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, this one has the largest planned enrollment, is the only one that started in 2022, is the only one in phase 3, and was the 2nd registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →9 of the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75 · Women only
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Sites in China
Ages 18–70 · Women only
Xijing Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 18–65 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 498 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 50 across the 12 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 4 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172217Qilu Hospital of Shandong UniversityThe Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | 2027-02-28 |
| NCT07205497Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityQL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer | 2027-03-30 |
| NCT07876154Xijing HospitalIparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer | 2027-07 |
| NCT07286253Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityQL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial | 2027-09-30 |
| NCT07141186Tianjin Medical University Cancer Institute and HospitalQL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab; Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab
Subjects must provide sufficient archival or newly obtained tumor tissue samples to determine PD-L1 expression level to be eligible for screening.During the screening phase, eligible subjects will be stratified by use of bevacizumab (yes vs no), prior concurrent chemoradiation therapy (yes vs no), and PD- L1 level (CPS \< 1 vs 1 ≤ CPS \< 10 vs CPS ≥ 10) and randomized 1:1 into the experimental or control arm.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab;Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QL1706 (5 mg/kg) + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
Drug: QL1706 · Drug: Paclitaxel injection · Drug: Cisplatin/Carboplatin
Placebo + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
Drug: Placebo · Drug: Paclitaxel injection · Drug: Cisplatin/Carboplatin
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Drug pages: Cisplatin · Carboplatin
Intravenous Infusion
PFS by BICR based on RECIST v1.1
PFS by BICR based on RECIST v1.1
Time frame: Informed consent until disease progression or death, which ever occurs first (up to approximately 24 months)
OS
OS
Time frame: From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 years
PFS and 12-month PFS rate assessed by investigator based on RECIST v1.1 criteria
PFS and 12-month PFS rate assessed by investigator based on RECIST v1.1 criteria
Time frame: Informed consent until disease progression or death, which ever occurs first (up to approximately 24 months
Plan to share: No — Involves subject privacy and does not intend to share
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 23 months after the start.
Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 23 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iparomlimab/Tuvonralimab
Qilu Pharmaceutical Co., Ltd. →